For instance, Pereira et al. demonstrated that GFAP levels increased in subjects with amyloid pathology and were capable of predicting amyloid beta positron emission tomography (Aβ-PET) positivity with an area under the curve (AUC) of 0.76, outperforming cerebrospinal fluid (CSF) GFAP and other glial markers [104]. This evidence concerns the gene GFAP and amyloidosis.